公开(公告)号：US11786534B2

公开(公告)日：2023-10-17

申请号：US17430208

申请日：2020-02-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Fuyuki Yamamoto ,  Takashi Mizutani ,  Hidefumi Kasuga ,  Hirokazu Fuchida ,  Shoki Hara ,  Yu Kobayakawa ,  Yoshio Ogino

IPC分类号： A61K31/519 ,  C07D487/04 ,  A61K31/5377 ,  A61P35/00 ,  C07D519/00

CPC分类号： A61K31/5377 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

摘要： The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11634395B2

公开(公告)日：2023-04-25

申请号：US17000807

申请日：2020-08-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  A61P35/00 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/107

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

公开(公告)号：US20200157066A1

公开(公告)日：2020-05-21

申请号：US16751555

申请日：2020-01-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/107 ,  A61P35/00

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

公开(公告)号：US20140343038A1

公开(公告)日：2014-11-20

申请号：US14348339

申请日：2012-09-28

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Toshihiro Sakamoto ,  Takashi Mita ,  Kazuaki Shibata ,  Yoshio Ogino ,  Hideya Komatani

IPC分类号： C07D471/04 ,  C07D409/12 ,  C07D403/12 ,  C07D401/14 ,  C07D409/14 ,  C07D405/12 ,  C07D405/14 ,  C07D495/04 ,  C07D417/14 ,  C07D417/12 ,  C07D413/12 ,  C07D401/12 ,  C07D403/14

CPC分类号： C07D471/04 ,  A61K31/53 ,  A61K31/535 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04

摘要： The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).

摘要翻译： 本发明提供具有Syk抑制作用的下述通式（I）表示的化合物或其盐（式中，R 1表示氢原子或者可以具有取代基的C 1〜C 6烷基; A表示氢原子， 任选取代的C 1 -C 8烷基，任选取代的C 2 -C 6烯基，任选取代的C 2 -C 6炔基，任选取代的C 3 -C 10环烷基，任选取代的C 6 -C 14芳族烃基，任选取代的4 至10元不饱和杂环基或任选取代的4-至10-元饱和杂环基，或任选地与R 1一起形成4-至10-元不饱和杂环或4-至10-元饱和杂环 和氮原子键合; R2表示氢原子或任选取代的C 1 -C 6烷基; B表示任选取代的不饱和杂环基）。

公开(公告)号：US10370372B2

公开(公告)日：2019-08-06

申请号：US15771487

申请日：2016-11-25

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa Minamiguchi ,  Shigeo Okajima ,  Takahiro Asai ,  Masanori Asai ,  Yoshio Ogino

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K31/519 ,  A61K31/55 ,  A61P35/00

摘要： To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).

公开(公告)号：US09145414B2

公开(公告)日：2015-09-29

申请号：US14348339

申请日：2012-09-28

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Toshihiro Sakamoto ,  Takashi Mita ,  Kazuaki Shibata ,  Yoshio Ogino ,  Hideya Komatani

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  A61K31/53 ,  A61K31/535 ,  A61P35/00

CPC分类号： C07D471/04 ,  A61K31/53 ,  A61K31/535 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04

摘要： The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).

摘要翻译： 本发明提供具有Syk抑制作用的下述通式（I）表示的化合物或其盐（式中，R 1表示氢原子或者可以具有取代基的C 1〜C 6烷基; A表示氢原子， 任选取代的C 1 -C 8烷基，任选取代的C 2 -C 6烯基，任选取代的C 2 -C 6炔基，任选取代的C 3 -C 10环烷基，任选取代的C 6 -C 14芳族烃基，任选取代的4 至10元不饱和杂环基或任选取代的4-至10-元饱和杂环基，或任选地与R 1一起形成4-至10-元不饱和杂环或4-至10-元饱和杂环 和氮原子键合; R2表示氢原子或任选取代的C 1 -C 6烷基; B表示任选取代的不饱和杂环基）。

公开(公告)号：US10889555B2

公开(公告)日：2021-01-12

申请号：US16751555

申请日：2020-01-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  C07D413/12 ,  A61P35/00 ,  C07D417/12 ,  C07D491/107 ,  C07D413/14

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.